3-Hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor (pravastatin) inhibits endothelial cell proliferation dependent on G1 cell cycle arrest

Anti-Cancer Drugs

Volumn 15, Issue 6, 2004, Pages 625-632

  Asakage, Masahiro ^a,b   Tsuno, Nelson H ^a   Kitayama, Joji ^a   Kawai, Kazushige ^a   Okaji, Yurai ^a   Yazawa, Kentaro ^a   Kaisaki, Shoichi ^a   Takahashi, Koki ^a   Nagawa, Hirokazu ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Angiogenesis inhibitors; Cell cycle; Cell proliferation; Endothelial cells; Statins

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN E; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MATRIX METALLOPROTEINASE; PRAVASTATIN; SCLEROPROTEIN;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CELL ADHESION; CELL CYCLE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL TYPE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG MECHANISM; DRUG POTENCY; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MITOSIS INHIBITION; MORBIDITY; MORTALITY; PRIORITY JOURNAL; TUMOR GROWTH;

ANGIOGENESIS INHIBITORS; APOPTOSIS; CDC2-CDC28 KINASES; CELL DIVISION; CELLS, CULTURED; CYCLIN E; CYCLIN-DEPENDENT KINASE 2; CYCLINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; EXTRACELLULAR MATRIX; G1 PHASE; GENE EXPRESSION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEOVASCULARIZATION, PATHOLOGIC; POLYISOPRENYL PHOSPHATES; PRAVASTATIN; RANDOMIZED CONTROLLED TRIALS; UMBILICAL VEINS;

EID: 3142723163     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000131680.83518.91     Document Type: Article

References (30)

1. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343:425-430.
2. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000; 101:207-213.
3. Gray-Bablin J, Rao S, Keyomarsi K. Lovastatin induction of cyclin-dependent kinase inhibitors in human breast cells occurs in a cell cycle-independent fashion. Cancer Res 1997; 57:604-609.
4. WAF1/CIP1 in human prostate carcinoma cells. J Biol Chem 1998; 273:10618-10623.
5. 1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53. Oncogene 1998; 17:2393-2402.
6. Kip1 accumulation during the cell cycle. Science 1996; 271:1861-1864.
7. Kip1. J Am Soc Nephrol 1998; 9:2235-2243.
8. WAF1/CIP1/SDI1 in a p53-independent manner. J Biol Chem 1997; 272:27224-27229.
9. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1:27-31.
10. Yoshida M, Szente BE, Kiely JM, Rosenzweig A, Gimbrone Jr MA. Phosphorylation of the cytoplasmic domain of E-selectin is regulated during leukocyte-endothelial adhesion. J Immunol 1998; 161:933-941.
11. Tomozawa S, Nagawa H, Tsuno N, Hatano K, Osada T, Kitayama J, et al. Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522. Br J Cancer 1999; 81:1274-1279.
12. Zukowska-Grojec Z, Karwatowska-Prokopczuk E, Rose W, Rone J, Movafagh S, Ji H, et al. Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium. Circ Res 1998; 83:187-195.
13. Grundy SM. Statin trials and goals of cholesterol-lowering therapy. Circulation 1998; 97:1436-1439.
14. Sumi S, Beauchamp RD, Townsend Jr CM, Uchida T, Murakami M, Rajaraman S, et al. Inhibition of pancreatic adenocarcinoma cell growth by lovastatin. Gastroenterology 1992; 103:982-989.
15. 1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci USA 1999; 96:7797-7802.
16. Kawata S, Yamasaki E, Nagase T, Inui Y, Ito N, Matsuda Y, et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 2001; 84:886-891.
17. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-1186.
18. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267:10931-10934.
19. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86:353-364.
20. Egashira K, Hirooka Y, Kai H, Sugimachi M, Suzuki S, Inou T, et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994; 89:2519-2524.
21. Salonen R, Nyssonen K, Porkkala-Sarataho E, Salonen JT. The Kuopio Atherosclerosis Prevention Study (KAPS): effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression. Am J Cardiol 1995; 76:34C-39C.
22. Bartek J, Bartkova J, Lukas J. The retinoblastoma protein pathway in cell cycle control and cancer. Exp Cell Res 1997; 237:1-6.
23. Vincent L, Soria C, Mirshahi F, Opolon P, Misha Z, Vannier JP, et al. Cerivastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase, inhibits endothelial cell proliferation induced by angiogenic factors in vitro and angiogenesis in in vivo models. Arterioscler Thromb Vasc Biol 2002; 22:623-629.
24. Li X, Liu L, Tupper JC, Bannerman DD, Winn RK, Sebti SM, et al. Inhibition of protein geranylgeranylation and RhoA/RhoA kinase pathway induces apoptosis in human endothelial cells. J Biol Chem 2002; 277:15309-15316.
25. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000; 6:1004-1010.
26. Park HJ, Kong D, Iruela-Arispe L, Begley U, Tang D, Galper JB. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA. Circ Res 2002; 91:143-150.
27. Weis M, Heeschen C, Glassford AJ, Cooke JP. Statins have biphasic effects on angiogenesis. Circulation 2002; 105:739-745.
28. Hanahan D. Signaling vascular morphogenesis and maintenance. Science 1997; 277:48-50.
29. Bellosta S, Via D, Canavesi M, Pfister P, Fumagalli R, Paoletti R, et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 1998; 18:1671-1678.
30. Chen J, Zhang ZG, Li Y, Wang Y, Wang L, Jiang H, et al. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol 2003; 53:743-751.